Реестр препаратов-кандидатов для лечения и профилактики COVID-19
Clinical trials are being conducted to evaluate the use of COVID-19 convalescent plasma to treat patients with severe or immediately life-threatening COVID-19 infections.
COVID-19 convalescent plasma is not intended for prevention of the infection.
- To participate in these trials, investigators should submit requests to the FDA for investigational use under the traditional IND regulatory pathway.
- In addition to clinical trials, licensed physicians may obtain COVID-19 convalescent plasma for an individual patient through the process of single patient eINDs.
Ravulizumab is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria and the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Радотиниб - ингибитор тирозинкиназы BCR / ABL (TKI).
Prevent and treat respiratory complications in immunosuppressed cancer patients.
Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors.
CD24Fc is designed to modulate host inflammatory response to tissue injuries which is believed to be involved in autoimmune disease, cancer, graft-versus-host disease (GvHD) and metabolic syndromes.
Has a dual mechanism of action. First, CD24Fc binds DAMPs (Danger-Associated Molecular Patterns), trapping the inflammatory stimuli to prevent their interaction with TLRs (Toll-like receptors). Second, CD24Fc binds Siglec G/10 and regulates host response to tissue injuries Siglec G/10-associated SHP1 inhibitory signaling. Both mechanisms likely act in concert to modulate immune responses.
Remdesivir is a monophosphoramidate prodrug of remdesivirtriphosphate (RDV-TP), an adenosine analog that acts as an inhibitor of RNA-dependent RNA polymerases (RdRps). Remdesivir-TP competes with adenosine-triphosphate for incorporation into nascent viral RNA chains. Once incorporated into the viral RNA at position i, RDV-TP terminates RNA synthesis at position i+3. Because RDV-TP does not cause immediate chain termination (i.e., 3 additional nucleotides are incorporated after RDV-TP), the drug appears to evade proofreading by viral exoribonuclease (an enzyme thought to excise nucleotide analog inhibitors).
Статус Emergency use authorization (EUA) FDA.
Программа расширенного доступа в странах Евросоюза.
ЕМА выдало статус Conditional marketing authorisation.
Противовирусный препарат семейства азолоазинов, гетероциклическим соединениям, структурно напоминающим азотистые основания, из которых состоят ДНК и РНК.
Метилтионитрооксодигидротриазолотриазинид натрия (Триазавирин) представляет собой синтетический аналог оснований пуриновых нуклеозидов (гуанина).
Противовирусный препарат для лечение хронического гепатита С у взрослых (в комбинации с интерфероном альфа-2b или пэгинтерфероном альфа-2b).
Ruxolitinib is a janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.
Sargramostim is primarily used for myeloid reconstitution after autologous or allogeneic bone marrow transplantation. It is also used to treat neutropenia induced by chemotherapy during the treatment of acute myeloid leukemia. It also used as a medical countermeasure for treating people who have been exposed to sufficient radiation to suppress bone marrow myelogenesis.